Background
==========

Gastric cancer is the second most common cause of cancer death worldwide, but incidence and mortality rates show large variations across different countries. Japan and China show the highest incidence rates of gastric cancer of 80-115 cancers/100,000 population and 32-59 cancers/100,000 population respectively, while in other Asian counties, such as India, Bangladesh, and Thailand, the incidence rates are much lower (10.6, 1.3, and 7.1 per 100,000 populations, respectively). Also within Europe, incidence and mortality rates differ between countries. Portugal has the highest incidence rates (33.2/100,000) whereas other countries in Western Europe show incidence rates of 19.4 per 100,000 populations. In the Netherlands it ranks fifth as a cause of cancer death with incidence rates of 14.6/100,000. In Africa, gastric cancer is infrequent, with incidence rates varying between 6.9/100,000 in Northern Africa, 12.9/100,000 in Eastern Africa, 11.9/100,000 in Southern Africa and 7.0/100,000 in Western Africa (Table [1](#T1){ref-type="table"}) \[[@B1]-[@B3]\].

###### 

Incidence rates of gastric cancers per 100,000 populations.

                   Incidence rates                         Incidence rates
  ---------------- ----------------- --------------------- -----------------
  **Japan**        80-115            **Netherlands**       14.6
  **China**        32-59             **Western Europe**    19.4
  **India**        10.6              **Northern Africa**   6.9
  **Bangladesh**   1.3               **Eastern Africa**    12.9
  **Thailand**     7.1               **Southern Africa**   11.9
  **Portugal**     33.2              **Western Africa**    7.0

According to the Correa model, intestinal type gastric cancers arise through a sequence of events, starting with chronic active gastritis due to infection with *Helicobacter pylori*(*H. pylori*). This chronic inflammatory process may lead to atrophy, intestinal metaplasia followed by dysplasia and eventually may lead to invasive adenocarcinoma \[[@B4]\].

The mechanism by which *H. pylori*contributes to gastric carcinogenesis is still largely unknown. However, we do know that gastric cancer is the result of accumulation of (epi)genetic changes. In gastric cancer, at least two types of genetic instability play a role. Microsatellite instability (MSI) occurs in cancers associated with Lynch syndrome or hereditary non-polyposis colorectal cancer (HNPCC), and in 10-15% of sporadic gastric cancers due to *hMLH1*promoter hypermethylation \[[@B5],[@B6]\]. However, the majority of gastric cancers show chromosomal instability, resulting in DNA copy number aberrations that can be analyzed in detail by high resolution array comparative genomic hybridization (array CGH). In a previous study using chromosome based comparative genomic hybridization (CGH), we were unable to demonstrate that there are specific chromosomal alterations which are associated with *H. pylori*infection \[[@B7]\].

Infection with *H. pylori*is important in the etiology of gastric cancer, consequently high incidences of gastric cancer are observed in areas with high prevalence of *H. pylori*infection, like Asia. However, despite high frequencies of *H. pylori*infection in Africa, gastric cancer is infrequent in Africa, a phenomenon often referred to as the \'African enigma\' \[[@B8],[@B9]\]. We hypothesize that geographical differences in environmental factors, including infection with *H. pylori*, and host factors are reflected by different biological characteristics of the tumors from those areas. Therefore, we compared MSI status and DNA copy number profiles in gastric cancer patients from United Kingdom (UK) and South Africa (SA).

Methods
=======

Material
--------

A total of 67 gastric adenocarcinomas were included in this study. Of these, 33 gastric adenocarcinomas were obtained from Leeds (Leeds, General Infirmary, UK) and 34 gastric adenocarcinomas were obtained from Pretoria (Prinshof Campus, Pretoria, South Africa), of which 25 were obtained from native South African patients (native SA) and 9 from Caucasian South African patients (Caucasian SA), respectively. All tumors were randomly selected after testing for proper DNA quality as previously described \[[@B10]\]. All gastric adenocarcinomas were staged according to the TNM classification (5th edition) for the grading and to the Laurén\'s classification for morphology \[[@B11]\]. The study was approved by the Institutional Review Board and was in accordance with local medical ethical regulations.

DNA isolation procedure
-----------------------

DNA was isolated from formalin-fixed and paraffin embedded gastric cancer material as described previously,\[[@B12],[@B13]\] using the QIAamp microkit (Qiagen, Hilden, Germany). DNA concentrations were measured using a Nanodrop ND-1000 spectrophotometer (Isogen, IJsselstein, The Netherlands) and DNA quality was assessed by isothermal amplification \[[@B10]\]. Genomic DNA isolated from peripheral blood obtained from eighteen healthy females or males was pooled to use as normal reference.

Microsatellite instability (MSI) analysis
-----------------------------------------

MSI analysis was performed using the MSI Analysis System (MSI Multiplex System Version 1.1, Promega) consisting of five nearly monomorphic mononucleotide markers *(BAT-25, BAT-26, NR-21, NR-24, MONO-27)*according to the manufacturer\'s instructions. PCR products were separated by capillary electrophoresis using an ABI 3130 DNA sequencer (Applied Biosystems, Foster City, CA, USA), and analyzed using GeneScan 3100 (Applied Biosystems, Foster City, CA, USA). An internal lane size standard was added to the PCR samples for accurate sizing of alleles and to adjust for run-to run variations. When all markers were stable, the tumor was interpreted as microsatellite stable (MSS). The tumor was interpreted as MSI-low (MSI-L) if one marker was instable and MSI-high (MSI-H) if two or more markers showed instability. MSI-L tumors were included in the MSS category in further analysis. Due to polymorphisms\[[@B14]\] in the South African population, native South African tumors were classified as MSI when three or more markers were instable.

Array CGH
---------

Array CGH was performed as described before \[[@B12],[@B15]\]. Briefly, 600 ng tumor and normal reference DNAs were labeled by random priming (Bioprime DNA Labeling System, Invitrogen, Breda, The Netherlands) and hybridized onto a BAC array containing approximately 6000 clones, consisting of the Sanger BAC clone set with an average resolution along the whole genome of 1.0 Mb, the OncoBac set, containing approximately 600 clones corresponding to 200 cancer-related genes, and selected clones of interest obtained from the Children\'s Hospital Oakland Research Institute (CHORI) to fill gaps larger than 1 Mb on chromosome 6 and to have full coverage contigs of regions on chromosome 8, 13 and 20. All clones were printed in triplicate on Nexterion slides (Schott Nexterion, Jena, Germany). Subsequent analysis was performed according to the clone position from the UCSC May 2004 freeze of the Human Genome Golden Path <http://genome.ucsc.edu>.

Image acquisition and data analysis
-----------------------------------

Images of the arrays were acquired by scanning (Agilent DNA Microarray scanner, Agilent Technologies, Palo Alto, USA) and Bluefuse software version 3.4 (BlueGnome, Cambridge, UK) was used for automatic feature extraction. Spots were excluded when the quality flag was below 1 or the confidence value was below 0.1. Log~2~tumor to normal ratio was calculated for each clone and median block normalization was used to normalize the data. Quality of array CGH profiles was measured by calculating a median absolute deviation value of chromosome 2 (MAD2) \[[@B10]\]. Array CGH profiles with MAD2 values \>0.18 were excluded from further analysis. For determining copy number gains and losses, the R package CGH call was used \[[@B16]\]. Output of the CGH call analysis was used for CGH region analysis to compress the data, using a threshold for average error rate of 0.001 \[[@B17]\]. Hierarchical cluster analysis was performed using the WECCA program, with the parameter total linkage \[[@B18]\].

Array data can be accessed using the Gene Expression Omnibus (GEO) <http://www.ncbi.nlm.nih.gov/geo/>, under accession number GSE22789.

Statistical analysis
--------------------

Significance of differences for categorical variables between different categories was tested using a chi-square test. One-way ANOVA with Bonferroni correction was used to calculate significant differences for continuous variables between Caucasian SA, native SA, and UK patients (SPSS 12.0.1 for Windows, SPSS Inc, Chicago, IL, USA). P values less than 0.05 were considered to be significant.

Supervised analysis was performed using the non-parametric Mann-Whitney two-sample test (CGH test \[[@B19]\]). Alterations in patterns between different tumor groups were compared using a binomial differential proportion test. The test procedure included a permutation-based false discovery rate correction for multiple testing \[[@B20]\]. Two-sided p values less than 0.05 and false discovery rates below 0.15 were considered to be significant.

Results
=======

Clinicopathological data
------------------------

The mean age of the UK gastric cancer patients was 73.3 years (range 51-96), mean age of the Caucasian SA patients was 68.0 years (range 56-84) and the mean age of the native SA patients was 56.5 years (range 29-79). One-way ANOVA with Bonferroni correction yielded a significant difference between the mean age of the patients between native and Caucasian SA patients (p = 0.03) and between native SA and UK patients (p \< 0.001), but not between Caucasian SA and UK patients (n.s).

There was no significant difference between patients of different geographical location and gender, tumor stage (T-category) and lymph node stage (N-category). UK gastric cancers showed significantly more diffuse type morphology compared to South African gastric cancers (p = 0.002). Overview of patient and tumor characteristics is given in Table [2](#T2){ref-type="table"}.

###### 

Tumor and patient characteristics of the 67 tumors used for MSI and array CGH analysis.

  ID   gender   age   Tumor type   T    N    origin      MSI status   Cluster number   Cluster order   \% events   \% gains   \% losses
  ---- -------- ----- ------------ ---- ---- ----------- ------------ ---------------- --------------- ----------- ---------- -----------
  1    F        62    intestinal   T2   N1   Cauc SA     MSS          5                34              3.2         3.2        0
  2    M        73    intestinal   T2   N2   Cauc SA     MSS          5                28              16.9        13.4       3.4
  3    F        59    intestinal   T2   N1   Cauc SA     MSS          5                26              26.5        15.1       11.4
  4    F        74    intestinal   T2   N1   Cauc SA     MSS          5                27              15.7        9.3        6.5
  5    M        56    intestinal   T3   N1   Cauc SA     MSI          \-               \-              15.6        10.3       5.3
  6    M        57    intestinal   T2   N1   Cauc SA     MSS          6                48              3.4         2.4        1.0
  7    F        84    intestinal   T1   N0   Cauc SA     MSS          6                43              10.9        7.9        3.1
  8    F        79    intestinal   T3   N0   Cauc SA     MSI          \-               \-              17.6        16.8       0.8
  9    M        68    intestinal   T3   N2   Cauc SA     MSS          5                25              32.1        24.3       7.7
  10   M        65    intestinal   T2   N0   native SA   MSI          \-               \-              1.7         1.7        0
  11   M        57    intestinal   T1   N0   native SA   MSI          \-               \-              0           0          0
  12   F        29    intestinal   T4   N0   native SA   MSS          6                37              28.3        26.2       2.1
  13   F        59    intestinal   T3   N1   native SA   MSS          6                42              10.6        5.3        5.3
  14   M        66    intestinal   T2   N1   native SA   MSS          5                31              6.4         6.4        0
  15   M        46    intestinal   T3   N2   native SA   MSS          5                35              3.2         3.2        0
  16   F        \-    diffuse      T4   N2   native SA   MSS          6                44              13.2        12.4       0.7
  17   M        51    intestinal   T3   N1   native SA   MSS          5                32              6.1         6.1        0
  18   F        49    intestinal   T3   N1   native SA   MSS          4                20              29.1        18.2       10.9
  19   M        56    intestinal   T3   N1   native SA   MSS          4                19              26.0        10.3       15.7
  20   M        48    intestinal   T3   N2   native SA   MSS          5                36              5.4         5.4        0
  21   M        65    mixed        T3   N1   native SA   MSI          \-               \-              18.2        16.3       1.9
  22   M        60    intestinal   T2   \-   native SA   MSS          6                41              14.0        11.3       2.7
  23   F        63    intestinal   \-   \-   native SA   MSS          6                38              17.1        10.7       6.4
  24   F        54    papillary    T2   N0   native SA   MSS          3                14              44.8        20.6       24.2
  25   M        67    intestinal   T3   N1   native SA   MSS          \-               \-              \-          \-         \-
  26   M        31    intestinal   T3   N1   native SA   MSS          5                24              41.1        28.4       12.7
  27   M        43    intestinal   T3   N1   native SA   MSI          \-               \-              9.9         9.9        0
  28   F        71    intestinal   T3   \-   native SA   MSS          5                33              3.7         2.7        1.0
  29   F        77    intestinal   T3   N1   native SA   MSS          5                30              12.7        7.1        5.5
  30   M        57    intestinal   T2   N0   native SA   MSS          \-               \-              \-          \-         \-
  31   M        79    intestinal   T3   N2   native SA   MSI          \-               \-              2.5         2.5        0
  32   M        57    intestinal   T4   N0   native SA   MSI          \-               \-              17.8        16.8       1.0
  33   M        56    mixed        T3   N1   native SA   MSS          4                17              42.2        21.3       20.9
  34   F        49    mixed        T3   N3   native SA   MSS          5                29              22.3        19.2       3.2
  35   F        82    diffuse      T1   N0   UK          MSS          6                46              11.2        10.3       1.0
  36   M        81    diffuse      T3   N2   UK          MSS          4                22              15.7        7.2        8.5
  37   M        71    diffuse      T2   N1   UK          MSS          7                53              18.4        14.7       3.7
  38   M        73    intestinal   T2   N0   UK          MSS          2                11              26.0        17.2       8.8
  39   F        65    diffuse      T2   N3   UK          MSS          6                45              15.0        12.0       3.1
  40   F        58    diffuse      T3   N3   UK          MSS          1                6               25.7        13.7       12.0
  41   F        51    diffuse      T3   N3   UK          MSS          1                7               22.4        16.5       6.0
  42   M        91    intestinal   T1   N0   UK          MSS          7                56              49.2        27.6       21.6
  43   M        71    diffuse      T3   N2   UK          MSS          7                49              40.6        19.8       20.8
  44   M        73    intestinal   T2   N1   UK          MSS          1                5               21.0        8.2        12.9
  45   M        64    diffuse      T2   N0   UK          MSS          7                50              14.9        10.3       4.6
  46   F        71    intestinal   T1   N0   UK          MSS          1                4               40.8        13.4       27.4
  47   F        60    intestinal   T4   N1   UK          MSS          3                16              30.1        15.6       14.5
  48   F        96    diffuse      T3   N0   UK          MSS          2                12              41.0        25.0       16.0
  49   M        91    mixed        T3   N0   UK          MSS          6                40              16.0        11.4       4.6
  50   M        81    diffuse      T2   N0   UK          MSS          2                10              37.7        17.2       20.4
  51   F        83    intestinal   T2   N0   UK          MSS          7                51              14.5        10.5       4.0
  52   F        82    intestinal   T3   N1   UK          MSS          6                47              2.2         2.2        0
  53   F        77    intestinal   T3   N1   UK          MSS          6                39              19.5        11.1       8.5
  54   M        74    mixed        T2   N1   UK          MSS          2                8               44.8        22.4       22.3
  55   F        59    diffuse      T3   N1   UK          MSS          3                15              26.4        18.1       8.2
  56   M        77    mixed        T3   N2   UK          MSS          1                3               24.1        13.7       10.3
  57   M        75    intestinal   T2   N0   UK          MSS          2                9               36.9        18.2       18.7
  58   M        64    diffuse      T3   N3   UK          MSS          2                13              35.3        20.2       15.1
  59   M        71    intestinal   T3   N1   UK          MSS          1                2               31.0        11.7       19.3
  60   F        74    diffuse      T3   N2   UK          MSS          4                23              23.2        14.7       8.4
  61   M        81    intestinal   T2   N0   UK          MSI          \-               \-              10.7        8.7        2.0
  62   F        74    mixed        T3   N2   UK          MSS          4                18              30.4        17.9       12.5
  63   M        67    mixed        T3   N1   UK          MSS          7                52              12.3        6.4        5.9
  64   M        73    intestinal   T3   N1   UK          MSS          4                21              15.2        7.3        7.9
  65   F        66    mixed        T3   N2   UK          MSS          7                55              34.3        18.7       15.6
  66   M        82    intestinal   T1   N1   UK          MSS          7                54              46.7        27.4       19.3
  67   F        62    mixed        T3   N0   UK          MSS          1                1               44.0        20.7       23.3

Percentages of events, gains and losses are given for all tumors of sufficient array CGH quality. Cluster number and order are listed for the 56 cases included in the cluster analysis.

F: female, M: male, T: T-stage, N: N-stage MSS: microsatellite stable, MSI: microsatellite instable, Cauc SA: Caucasian South African patients, native SA: native South African patients, UK: patients from United Kingdom, -: unknown.

Microsatellite instability (MSI) analysis
-----------------------------------------

Two out of nine (22%) Caucasian SA gastric cancers, six out of 25 (24%) native SA gastric cancers, and one out of 33 (3%) UK gastric cancers showed MSI. All other gastric cancers were MSS (Table [2](#T2){ref-type="table"}). Pearson chi-square yielded a significant difference between the three different tumor groups and MSI status (p \< 0.05).

Hierarchical cluster analysis
-----------------------------

We analyzed DNA from all gastric cancers by genome-wide array CGH analysis to unravel DNA copy number changes in tumors from different geographical location. MSI positive gastric cancers and gastric cancers with array CGH profiles with a MAD2 value above 0.18 were excluded for cluster analysis leaving 56 tumors (from 32 UK, 17 native SA and 7 Caucasian SA patients) for further analysis.

Hierarchical cluster analysis yielded seven clusters which were significantly correlated with gastric cancers of different geographical origin (p \< 0.001) (Figure [1](#F1){ref-type="fig"}). Clusters 1, 2 and 7 obtained only gastric cancers from UK patients. Clusters 3 and 4 comprised of gastric cancers from UK and native SA patients. Cluster 5 contained only gastric cancers from SA patients, and cluster 6 contained a mixture of tumors of all three groups (Table [2](#T2){ref-type="table"}).

![**Cluster analysis of 56 gastric adenocarcinomas of which 32, 17 and 7 were obtained from UK, native SA and Caucasian SA patients, respectively**. Hierarchical cluster analysis yielded 7 clusters significantly correlated with geographical origin of the tumors (p \< 0.001). Columns represent the different tumors and rows represent the different chromosomal regions, with chromosome 1 at the bottom and chromosome 22 at the top of the heatmap. DNA copy number gains and losses are indicated in green and red, respectively. The yellow and blue bar next to the cluster represents the chromosome separation.](1755-8794-4-7-1){#F1}

UK patients showed significantly more gastric adenocarcinomas of the diffuse type according to the Laurén classification\[[@B11]\] compared to SA patients (p = 0.002). We therefore repeated the cluster analysis including only intestinal type gastric carcinomas. Cluster membership of the remaining 12 tumors from UK patients and 12 and 7 tumors from native SA and Caucasian SA patients, respectively, was again significantly correlated to geographical origin of the patient (p \< 0.001). Moreover, when analyzing only UK gastric cancers, hierarchical cluster analysis did not separate intestinal and diffuse type gastric cancers, nor were any significant differences observed between these two morphological tumor types with supervised analysis using CGH test.

Cluster membership was independent of gender, tumor stage, lymph node stage and of age of the patients (categorized as \< 50 years of age *versu*s ≥ 50 years of age).

DNA copy number changes
-----------------------

We first compared the number of events, which was defined as percentage of clones showing a gain or loss. Gastric cancers from UK patients showed a higher number of events (27% (range 2-49%)) compared to cancers from Caucasian SA (16% (range 3-32%)) and native SA patients (16% (range 0-45%)) (p = 0.005). Cancers from UK, Causasian SA and native SA patients showed 15% (range 2-28%), 11% (range 2-24%) and 11% (range 0-28%) of gained clones respectively, and 12% (range 0-27%), 4% (range 0-11%) and 5% (0-24%) clones showing a loss, respectively. A significant difference in the percentage of clones showing a loss was observed between UK patients and Caucasian SA patients (p = 0.002) and between UK patients and native SA patients (p = 0.02).

Also, when looking only at microsatellite stable gastric cancers UK patients showed a higher number of events (27% (range 2-49%)) compared to microsatellite stable cancers from Caucasian SA and native SA patients (16% (range 3-32%) and 19% (range 3-45%), respectively; p = 0.04). Microsatellite stable cancers from UK, Caucasian SA and native SA patients showed 15% (range 2-28%), 12% (range 2-24%) and 13% (range 3-28%) of gained clones, respectively. There was again a significant difference in percentages of clones showing a loss between cancers from UK and Caucasian SA patients (12% (range 0-27%) and 4% (range 0-11%), respectively; p = 0.04) and between cancers from UK and native SA patients (12% (range 0-27%) and 7% (range 0-24%) respectively; p = 0.04).

An overview of frequently altered (\>30%) chromosomal regions with gains and losses per tumor group is given in Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. Most frequently altered (\>30%) chromosomal regions observed in the UK tumors were gains on chromosomes 1p, 1q, 5p, 6p, 7p, 7q, 8q, 9q, 10p, 10q, 11p, 11q, 13q, 14q, 16p, 16q, 17p, 17q, 19p, 19q, 20p, 20q, 21q and 22q and losses on chromosomes 1p, 1q, 3p, 4p, 4q, 5q, 9p, 12q, 13q, 14q, 15q, 17q, 18q and 21q (Table [3](#T3){ref-type="table"}). Most frequent DNA copy number aberrations in the native SA patients were gains on the chromosomal regions 7p, 7q, 8q, 9q, 17q, 19p, 19q, 20p and 20q, and losses on 3p and 4q (Table [4](#T4){ref-type="table"}). Most frequently altered chromosomal regions in Caucasian SA patients were gains on 3q, 5p, 7p, 7q, 8p, 8q, 9q, 11q, 16p, 17q, 19p, 19q, 20p and 20q and losses on 3p, 4q and 9p (Table [5](#T5){ref-type="table"}). A summary of frequencies of gains and losses of all gastric cancers per tumor group is presented in Figures [2](#F2){ref-type="fig"} (UK), 3 (native SA) and 4 (Caucasian SA).

###### 

Detailed overview of frequent DNA copy number aberrations (\>30%) of tumors from UK patients.

  chromosomal aberrations   flanking clones   position (bp)                 segment size               
  ------------------------- ----------------- --------------- ------------- -------------- ----------- --------
  1p36.33-p36.21                              RP11-206L10     RP4-636F13    672780         12417597    11.74
                            1p31.1            RP5-944F13      RP11-246O4    69815162       83112098    13.30
                            1p21.3-p13.3      RP11-146P11     RP5-1077K16   95695632       107389118   11.69
  1q21.2-q23.1                                RP4-790G17      RP11-214H6    146971278      153444622   6.47
                            1q31.1-q31.3      RP11-134C1      RP11-75C23    184717073      194242465   9.53
  1q32.1-q32.2                                RP11-150l7      RP11-564A8    197877387      203602276   5.72
                            3p26.3            RP11-385A18     RP11-129K1    46140          2377366     2.33
                            3p25.1-p24.1      RP11-255O19     RP11-99M10    15780361       30799547    15.02
                            3p14.2            RP11-170K19     RP11-114P15   59701329       62639806    2.94
                            3p12.3-p11.2      RP11-103P13     RP11-91M15    75146113       96627928    21.48
                            4p16.1-q35.2      RP11-61G19      CTC-963K6     10275012       191158370   180.88
  5p15.33                                     RP11-811I15     CTD-2265D9    70262          2671745     2.60
                            5q11.1-q23.3      RP11-269M20     RP11-114H7    49913067       130460728   80.55
  6p21.32-p21.1                               RP11-79I1       RP11-121G20   33123932       44385866    11.26
  7p22.3-p22.1                                RP11-713A20     RP11-161C7    106471         6396697     6.29
  7p11.2                                      RP11-449G3      RP11-34J24    54413814       55403627    0.99
  7q22.1                                      RP11-10D8       RP11-163M5    98067793       101528379   3.46
  7q36.1                                      RP11-89P11      RP11-43l19    147485335      151131938   3.65
  7q36.3                                      RP11-58F7       RP11-120H14   157072238      158524109   1.45
  8q24.12-q24.3                               RP11-22A24      RP5-1109M23   120711365      146238749   25.53
                            9p24.3-p21.1      RP11-48M17      RP11-141J7    2136329        32469400    30.33
  9q33.3-q34.3                                RP11-205K6      RP11-424E7    126296075      138363252   12.07
  10p15.3                                     RP11-631M21     RP11-74N14    50000          1789100     1.74
  10p15.2                                     RP11-195B3                    3293007        3338470     0.05
  10q22.1                                     RP11-91A1       RP11-28E3     72033907       73573433    1.54
  11p15.5-p15.4                               CTC-908H22      RP11-304P12   178227         3140168     2.96
  11q12.2-q13.5                               RP11-286N22     RP11-30J7     60851860       76232373    15.38
                            12q21.2-q22       RP1-97G4        RP11-2K12     76228586       91346299    15.12
  13q11-q12.11                                RP11-94A1       RP11-61K9     18360157       19386914    1.03
                            13q21.2-q21.33    RP11-310K10     RP11-451E2A   60721181       71574154    10.85
  13q32.3                                     RP11-19J14      RP11-113F15   97851594       99328275    1.48
  13q33.3-q34                                 RP11-61I17      RP11-569D9    108847725      114103243   5.26
                            14q12             RP11-330O19     RP11-109D12   25538832       26345513    0.81
                            14q21.1-q21.3     RP11-88D14      RP11-94K16    36949212       48298851    11.35
                            14q31.1-q31.3     RP11-46l17      RP11-88N20    78630860       86772926    8.14
  14q32.31-q32.33                             RP11-367F11     RP11-815P21   101467534      105159201   3.69
                            15q14             RP11-294M6      RP11-79A5     33841939       35953471    2.11
  16p13.3                                     CTD-2148K8      RP11-89M4     87754          4697230     4.61
  16p13.2-p13.11                              RP11-475D10     RP11-489O1    8598165        15572359    6.97
  16p12.1-p11.2                               RP11-142A12     RP11-18H23    26595069       31443695    4.85
  16q21-q22.1                                 RP11-52B24      RP11-394B2    63708677       69365102    5.66
  16q23.3-q24.3                               RP11-483P21     RP11-566K11   82361609       88613383    6.25
  17p13.3-p13.1                               RP11-411G7      RP11-89A15    427024         8365794     7.94
  17p11.2                                     RP11-524F11     RP1-162E17    17343389       19251691    1.91
  17q11.2-q21.31                              RP11-138P22     RP11-374N3    23133763       41096064    17.96
  17q21.32-q21.33                             RP11-234J24     RP11-506D12   42655422       46333070    3.68
                            17q22-q23.2       RP11-143M4      RP11-139B3    47607556       51363278    3.76
  17q24.3-q25.3                               RP11-65C22      RP11-258N23   68165339       78308832    10.14
                            18q11.2-q23       RP11-5G23       RP11-396D4    21431314       71337306    49.91
  19p13.3-q13.43                              RP11-110A24     GS1-1129C9    134914         63771717    63.64
  20p13-q13.33                                RP11-530N10     CTB-81F12     9943           62393015    62.38
                            21q11.2-q22.11    RP11-72P4       RP11-41N19    13857799       30673984    16.82
  22q11.1-q11.21                              RP11-81H21      RP11-586I18   14754982       18976359    4.22
  22q12.3-q13.33                              RP11-90I17      CTB-99K24     35686144       49397088    13.71

###### 

Detailed overview of frequent DNA copy number aberrations (\>30%) of tumors from native SA patients.

  chromosomal aberrations   flanking clones   position (bp)                 segment size               
  ------------------------- ----------------- --------------- ------------- -------------- ----------- -------
                            3p14.2            RP11-734E15     RP11-137N22   59105371       61252524    2.15
                            4q35.2            RP11-354H17     CTC-963K6     190095484      191158370   1.06
  7p22.3-p11.2                                RP11-713A20     RP11-80l24    106471         55784518    55.68
  7q22.1                                      RP11-10D8       RP11-163M5    98067793       101528379   3.46
  8q24.3                                      RP11-472K18     RP5-1109M23   144481535      146238749   1.76
  9q33.3-q34.3                                RP11-91G7       RP11-424E7    124316484      138363252   14.05
  17q12-q21.31                                RP11-893G17     RP11-392O1    31506328       39091575    7.59
  17q21.32-q21.33                             RP1-62O9        RP11-506D12   44647598       46333070    1.69
  17q23.2-q25.3                               RP11-579A4      RP11-258N23   54149948       78451750    24.30
  19p13.3                                     RP11-110A24     CTC-1482H14   134914         5154803     5.02
  19p13.2-p13.11                              RP11-197O4      RP11-88I12    10248852       19023254    8.77
  19q12-q13.34                                CTC-1459F4      GS1-1129C9    32889410       63771717    30.88
  20p13-q13.33                                RP11-530N10     CTB-81F12     9943           62393015    62.38

###### 

Detailed overview of frequent DNA copy number aberrations (\>30%) of tumors from Caucasian SA patients.

  chromosomal aberrations   flanking clones   position (bp)                 segment size               
  ------------------------- ----------------- --------------- ------------- -------------- ----------- -------
                            3p14.2            RP11-48E21      RP11-641C17   60380670       60705094    0.32
  3q26.2-q26.31                               RP11-669J9      RP11-44A1     172392313      173855790   1.46
                            4q32.1-q35.2      RP11-192D11     CTC-963K6     159886665      191158370   31.27
  5p13.1-p12                                  RP11-17J3       RP11-55O15    40113135       44396362    4.28
  7p22.3-p21.3                                RP11-713A20     RP11-505D17   106471         7932634     7.83
  7q22.1                                      RP4-550A13      RP11-333G13   98512376       101153193   2.64
  8p23.1                                      RP11-241P12     RP11-589N15   9788949        11803111    2.01
  8q22.1-q22.3                                RP11-664H21     RP11-132E3    98618965       105402542   6.78
  8q24.21                                     RP11-28I2       RP11-1142f3   127563658      129620230   2.06
                            9p24.1-p23        RP11-165O14     RP11-91E3     5873408        9689968     3.82
  9q33.3-q34.3                                RP11-62A6       RP11-424E7    124479347      138363252   13.88
  11q13.3-q13.5                               RP11-554A11     RP11-98G24    68509550       77008323    8.50
  16p11.2                                     RP11-110P16     RP11-388M20   28675396       31163676    2.49
  17q12-q21.1                                 RP5-986F12      RP11-94L15    33099924       35227135    2.13
  17q25.1-q25.3                               RP11-41E12      RP11-258N23   68729134       78451750    9.72
  19p13.3-p13.11                              RP11-110A24     RP11-88I12    134914         19023254    18.89
  19q13.11-q13.43                             CTC-1325L16     GS1-1129C9    37623641       63771717    26.15
  20p13-q13.33                                RP11-48M7       CTB-81F12     3728265        62393015    58.66

![**Frequencies of gains and losses throughout the genome in all gastric adenocarcinomas from UK patients**. Clones are sorted by position per chromosome (1-22). Vertical lines indicate transition between chromosomes; dashed vertical lines indicate centromere position.](1755-8794-4-7-2){#F2}

![**Frequencies of gains and losses throughout the genome in all gastric adenocarcinomas from native SA patients**. Clones are sorted by position per chromosome (1-22). Vertical lines indicate transition between chromosomes; dashed vertical lines indicate centromere position.](1755-8794-4-7-3){#F3}

![**Frequencies of gains and losses throughout the genome in all gastric adenocarcinomas from Caucasian SA patients**. Clones are sorted by position per chromosome (1-22). Vertical lines indicate transition between chromosomes; dashed vertical lines indicate centromere position.](1755-8794-4-7-4){#F4}

Supervised analysis
-------------------

To identify biological differences between gastric cancers from different geographical origin, native SA tumors were compared with UK tumors using CGH test. Only MSS tumors were included in the supervised analysis. In total, 133 regions, located on different chromosomes, were significantly different (p \< 0.05 and fdr≤0.15) between these two patient groups. An overview of the significant chromosomal regions, including the fdr rates, is given in Table [6](#T6){ref-type="table"}. No significant differences were found between gastric cancers from UK and Caucasian SA patients or between gastric cancers from native and Caucasian SA patients.

###### 

Detailed overview of the supervised analysis using CGH test.

  cytoband         region start (bp)   region end (bp)   p-value   fdr      cytoband          region start (bp)   region end (bp)   p-value   fdr
  ---------------- ------------------- ----------------- --------- -------- ----------------- ------------------- ----------------- --------- --------
  1p36.33          672780              1359795           0.04      0.15     11p14.2-p14.1     27033269            27371257          0.05      0.15
  1p36.32-p36.31   3386389             6294064           0.03      0.12     11q13.3           68509550            69323966          0.04      0.14
  1p36.21-p36.13   12798944            15683816          0.03      0.12     11q13.3-q13.4     69314721            70472869          0.04      0.14
  1p31.2           67178936            69303906          0.04      0.14     11q22.1-q22.2     98930611            101405228         0.03      0.12
  1p31.1           69815162            76679895          0.01      0.06     11q22.2-q22.3     102010610           102424014         0.03      0.12
  1p31.1           77428804            77820126          \<0.01    0.04     12q21.2           76570565            78724263          0.04      0.14
  1p21.2-p21.1     101684496           104502748         0.03      0.12     13q21.31-q21.33   61335626            69275204          0.04      0.14
  1q31.1-q31.2     184717073           188976520         0.01      0.09     14q21.1           39694531            42171623          0.02      0.10
  1q31.2-q31.3     189822405           193082884         0.02      0.10     14q21.2           42965408            44043547          0.01      0.09
  1q31.3           193336091           194242465         0.01      0.08     14q21.2-q21.3     45258184            48298851          0.03      0.12
  1q31.3           195068870           195629725         0.03      0.12     15q14             33841939            35953471          0.04      0.14
  3p26.3           46140               2377366           \<0.01    0.03     15q22.2           57373165            61214280          0.02      0.09
  3p24.3           17181327            18148477          \<0.01    0.03     15q23             65816865            68768615          0.02      0.09
  3p24.3           19033520            21742232          \<0.01    0.03     15q23-q24.2       69188639            73645336          0.05      0.15
  3p24.3-p24.1     22747912            27531283          0.02      0.10     15q24.2-q25.2     74334873            81024206          0.03      0.12
  3p21.31          46545403            47371983          0.05      0.15     16p13.2-p13.12    8777494             12522798          0.05      0.15
  3p21.31          47384745            50114898          0.04      0.14     16p11.2           28675396            31163676          \<0.01    0.04
  3p21.31-p21.2    50533656            51418837          0.01      0.09     16q24.1           82993991            83622386          0.05      0.15
  3p21.31-p21.2    51390596            52007218          0.02      0.09     16q24.1           84123856            84922042          0.02      0.09
  3p21.1           52658450            53621497          0.01      0.09     16q24.2-q24.3     86986672            87452904          0.03      0.12
  3p12.3           76450939            79097142          0.02      0.09     16q24.3           87848795            88465228          0.02      0.09
  3p12.3-p12.2     79197544            82066233          \<0.01    0.04     16q24.3           88398231            88613383          0.01      0.07
  3p12.2-p12.1     82657794            84801874          \<0.01    0.03     17p13.3           427024              1071560           \<0.01    0.03
  3p12.1-p11.2     85234579            87730259          \<0.01    0.03     17p13.3-p13.2     2026966             4169913           0.04      0.14
  3p11.1           88915283            89771786          \<0.01    0.04     17p13.2           4810523             5166678           0.01      0.09
  3q11.2           95569618            96250439          0.01      0.05     17p13.1           6780962             7477414           \<0.01    0.03
  3q25.1-q25.33    151508469           161536133         0.03      0.12     17p13.1           7436435             7682367           \<0.01    0.03
  3q25.33-q26.1    162044657           164516640         0.03      0.12     17p11.2           17343389            19251691          0.04      0.14
  3q26.1           165289729           167697600         0.05      0.15     17q11.2           23133763            28423820          0.02      0.09
  3q26.31-q26.32   174848631           180449332         0.05      0.15     17q11.2-q12       28664889            29147086          0.02      0.09
  4p15.32-p14      17799729            36260048          0.02      0.11     17q25.1           69709369            71238958          0.01      0.09
  4p14             36998587            37497326          0.01      0.09     17q25.1-q25.3     71406319            77588058          0.03      0.12
  4p14             37851044            38103870          0.02      0.11     18q11.2           21431314            21774952          0.01      0.05
  4p14-p12         38087293            46781512          0.01      0.09     18q11.2           22104619            22931012          \<0.01    0.04
  4q12             58332155            59148507          0.04      0.14     18q12.1           23970882            24526449          0.02      0.10
  4q12-q13.1       59679465            62653308          0.02      0.10     18q12.1           25034674            26878315          0.01      0.08
  4q13.3           74322497            76429795          0.03      0.12     18q12.1           27447009            28415095          0.01      0.09
  4q13.3-q21.21    76495364            79353372          0.02      0.09     18q12.1           29409483            30219417          0.01      0.09
  4q21.21          79222718            80683287          0.03      0.12     18q12.1-q12.2     30773824            31588529          0.01      0.06
  4q33-q34.3       172094999           178721484         0.02      0.10     18q22.1           60340433            61310295          0.03      0.12
  4q34.3           178969859           179599683         0.01      0.09     18q22.1           61623805            62645202          0.03      0.12
  4q34.3           180819690           183096645         0.02      0.10     18q22.1-q22.3     63092764            68041625          0.03      0.12
  4q35.1           184503994           186178296         0.03      0.12     19p13.3           134914              913289            0.01      0.08
  5q11.2           50971745            52055659          0.04      0.14     19p13.3           902641              5009969           \<0.01    0.04
  5q11.2           52909242            56437163          0.03      0.12     19p13.3           5663923             6519297           \<0.01    0.01
  5q11.2-q12.1     56921490            58947885          0.02      0.09     19p13.3-p13.2     6523443             9826740           \<0.01    \<0.01
  5q14.3           82802677            86118543          0.05      0.15     19p13.2-p13.12    10248852            15116365          \<0.01    0.03
  5q23.2           122463056           123527915         0.05      0.15     19p13.12-p13.11   15415833            17777501          \<0.01    0.01
  7p22.1-p21.3     6983150             7932634           \<0.01    0.02     19p13.11          18202507            19023254          \<0.01    0.03
  7p21.3-p21.2     9256088             14085902          \<0.01    \<0.01   19p12             19877150            21504328          0.01      0.05
  7p21.2-p21.1     14342152            19957111          \<0.01    0.01     19p12             22133662            22949959          0.01      0.05
  7q22.1           98651132            100929260         \<0.01    0.03     19q12             33315121            33507712          0.02      0.10
  8q24.21          130562467           131126185         0.05      0.15     19q12             34159370            34664148          0.02      0.11
  8q24.22          131641447           133561490         0.01      0.09     19q12             34960906            35766560          0.02      0.11
  8q24.22          134537164           136154996         0.02      0.11     19q12-q13.11      36958851            37518517          0.05      0.15
  8q24.22-q24.23   136472354           138543270         0.04      0.14     19q13.12-q13.13   40883472            43004503          0.03      0.13
  8q24.3           141395868           142790557         0.01      0.05     19q13.2-q13.32    46498596            50725496          0.03      0.12
  8q24.3           144790054           145357620         0.01      0.09     19q13.32-q13.33   52665374            54718281          0.03      0.12
  8q24.3           145585590           145953950         0.02      0.11     19q13.33-q13.43   55461670            63771717          \<0.01    0.01
  8q24.3           145893230           146238749         0.04      0.14     21q11.2-q21.1     13857799            18774434          \<0.01    0.03
  9p24.1-p23       8398601             9689968           0.04      0.14     21q21.1           20982315            21411332          \<0.01    0.03
  9p23             9684353             10554235          0.04      0.14     21q21.1-q21.2     22151920            22943367          \<0.01    0.03
  10q22.1          70824040            71674097          0.03      0.12     21q21.2           23491399            25568510          \<0.01    0.01
  10q22.1          72033907            73573433          0.02      0.09     21q21.3           26174732            26923374          0.02      0.09
  10q26.3          135110821           135301208         0.03      0.12     21q21.3-q22.11    28596969            30855176          0.03      0.12
  11p15.5          178227              626401            0.01      0.05     22q13.33          48473404            49397088          0.04      0.15
  11p15.5          1299306             1785278           \<0.01    0.03                                                                       

In total, 133 regions were significantly different (p \< 0.05 and fdr≤0.15) between UK and native SA tumors. The chromosomal regions, including the start and end positions, and the fdr rates are listed.

Discussion
==========

One of the main risk factors contributing to gastric cancer is infection with *H. pylori*, which causes a chronic active gastritis \[[@B4],[@B21]\]. In South Africa, gastric cancer is infrequent, while the prevalence of *H. pylori*infection is very high. Although differences in genotypes of *H. pylori*exist in different geographic areas, this African enigma can not only be explained by differences in virulent strains of *H. pylori*\[[@B22]-[@B24]\]. High prevalence of *vac*A s1b strain is observed in South Africa as well as in Brazil and Portugal, countries with high incidences of gastric cancer,\[[@B25]-[@B27]\] and frequencies of *CagA*antibodies were similar between patients with gastric neoplasia compared to healthy controls \[[@B28]\]. The prevalence of the different virulent strains in the present study is unknown. Since *H. pylori*is thought to play a major role in the initiation phase of gastric cancer development and most often already disappeared at time of gastric cancer diagnosis, it is impossible to accurately retrieve this information.

Besides the virulence of the infecting *H. pylori*strain, other factors influence gastric cancer risk, including environmental factors such as diet and socioeconomic status, and host factors, such as polymorphisms, which are involved in the inflammatory response to the infection \[[@B29],[@B30]\]. Knowing that the prevalence of *H. pylori*infection and incidences of gastric cancer are different in South Africa and Western Europe, we aimed to study if this would reflect in different patterns of gastric carcinogenesis.

The concept of the African enigma has been challenged since it has been suggested that the enigma could be explained due to lack of infrastructure and access to hospitals and care in African countries resulting in incomplete reporting of gastric cancer. However the incidence of gastric cancer would have been so dramatically underestimated that it has been stated that under-reporting by itself could not explain the lower frequencies of gastric cancer in African countries \[[@B31]\]. Also, when using the proportional frequency of gastric cancer compared to other cancer types in Africa, gastric cancer incidence remains very low \[[@B8]\]. Another criticism on the African enigma has been the high prevalence of HIV infection. A relatively large part of the African population would die of HIV before the age in which gastric cancer becomes more frequent. However, the low gastric cancer incidence in Africa was described before the HIV epidemic.

South African patients showed significantly more microsatellite instable gastric cancers compared to Western European patients. Also at the level of chromosomal instability clear differences were found, reflected by a significant correlation between cluster membership and geographical tumor origin, i.e. UK, native SA and Caucasian SA. Microsatellite instable gastric cancers are described to have fewer chromosomal aberrations compared to microsatellite stable gastric cancers \[[@B32],[@B33]\]. To rule out that tumors from South African patients cluster together by hierarchical cluster analysis due to the fact that these tumors show higher frequencies of microsatellite instability, only microsatellite stable gastric cancers were included in the hierarchical cluster analysis.

Not much has been reported about microsatellite status in gastric cancers from African patients. One study reported infrequent microsatellite instable gastric cancers in South African patients\[[@B34]\] which is in contrast with our findings which show a higher frequency of microsatellite instability in gastric cancers from SA patients compared to UK patients. Based on the present data, MSI does play an important role in gastric carcinogenesis in South Africa.

Several chromosomal aberrations are common in the three different tumor groups analyzed, including gains of chromosomes 7, 8q, 9q, 17q, 19 and 20 and losses of 3p and 4q, while other chromosomal changes are specific for each tumor group. In addition, gastric cancers from UK patients showed a significantly higher number of clones showing a loss compared to gastric cancers form South African patients. These results indicate different patterns of chromosomal instabilities in gastric cancers correlating to geographical origin of the patient.

The chromosomal aberrations of the UK tumors are comparable to other array CGH studies analyzing Western European tumors \[[@B12],[@B35]-[@B37]\]. To the best of our knowledge, this is the first array CGH study on gastric cancers from South African patients. Since several chromosomal regions are significantly different between gastric cancers from different geographical origin, and each region comprises multiple genes, further studies are needed to pinpoint candidate genes contributing to the differences in genomic profiles.

The higher frequency of diffuse gastric cancers from UK patients compared to the SA patients in the present study could be considered as a confounding factor. Contradicting results have been published either describing different or similar patterns of DNA copy number aberrations between intestinal and diffuse type gastric cancers \[[@B7],[@B33],[@B37]-[@B39]\]. In the context of the present study we believe that the differences in DNA copy number aberrations between UK and SA gastric cancers are independent of the histological tumor type. When repeating the cluster analysis with intestinal type carcinomas only, cluster membership again was significantly correlated with geographical origin of the tumors. Also supervised data analysis, i.e. testing copy number status of all genomic loci, did not reveal any significant differences in DNA copy number changes between intestinal and diffuse gastric cancers from UK patients. Furthermore, hierarchical cluster analysis including UK gastric cancers only did not separate intestinal and diffuse type gastric cancers. We therefore do not believe our findings to be influenced by distribution of histological types in this series. Question remains why diffuse type gastric cancers were more frequently observed in gastric cancers from UK patients compared to SA patients. Besides being a confounding factor, we can hypothesize that mutation of E-cadherin (*CDH1*), or other mechanisms disrupting the *CDH1*gene function such as epigenetic mechanisms or miRNAs, playing an important role in diffuse type gastric cancer, might play a minor role in SA gastric cancer patients due to different pathways of carcinogenesis, as shown in the present study by differences in patterns of DNA copy number aberrations. Also, the prevalence of *H. pylori*infection is very high in South Africa, and *H. pylori*infection mainly plays a role in intestinal type gastric cancers. This could also explain the higher number of intestinal type gastric cancers in SA patients.

Further, with respect to copy number changes in relation to histological types, chromosomal gains of 8q and 17q and losses of 3p have been described to be associated with intestinal type gastric cancers \[[@B33]\]. On the other hand, gains of 8q and 17q have been reported to be altered predominantly in diffuse type gastric cancers \[[@B38]\]. In the present study gains on chromosomes 8q and 17q and losses on 3p were common to both intestinal and diffuse type gastric cancers. In addition, these aberrations also were common in tumors from both UK and SA patients. Gains on chromosomes 13q and 19q have been found more frequently in diffuse type gastric cancers \[[@B33],[@B36],[@B38]\]. Again, in the present study, gains of these chromosomes were observed equally in intestinal and diffuse type gastric cancers. Gain of 19q was frequently observed in tumors from both geographical origins. Although gain of 13q was observed less frequently in tumors from SA patients compared to tumors from UK patients, still around 20-25% of the tumors of native SA patients show a gain of chromosome 13q, making it unlikely that tumor type has influenced cluster membership.

A limitation of the present study is the fact that native SA gastric cancer patients were significantly younger compared to Caucasian SA and UK gastric cancer patients. We previously showed that gastric cancers of young and elderly patients have different patterns of chromosomal aberrations \[[@B12]\]. We cannot rule out that also in these series, age might contribute to differences in DNA copy number profiles, however cluster analysis showed that gastric cancers from native SA patients were more similar to cancers from Caucasian SA patients, who have similar age as UK patients, indicating that cluster membership is independent of age in this respect. Overall, most differences were observed between UK and native SA tumors.

We realize that the present study is based on a heterogeneous group of gastric cancer patients, with different genetic background and different environmental factors, including *H. pylori*, diet and socioeconomic status, influencing gastric cancer risk. Statements on genotype influencing gastric cancer are very difficult to make since the degree of heterogeneity within each different patient group, i.e. UK, native SA and Caucasian SA, is unknown.

The patterns of genomic alterations in gastric cancers from UK and SA patients could gain clinical relevance in the future. In addition to surgery, gastric cancer treatment increasingly includes (neo)adjuvant chemotherapy and/or radiotherapy, however still without patients being stratified based on biological characteristics of their tumors. Clinical trials are underway in which also the value of genetic markers for predicting response to therapy are studied. In the end, stratification for therapy may include genomic alterations observed in tumors of patients from different geographical origin.

Conclusions
===========

We showed that gastric cancers of UK and SA patients are different in their patterns of genomic instability. Gastric cancers from SA patients show higher frequencies of microsatellite instability and different patterns of chromosomal aberrations compared to gastric cancers from UK patients. These results may suggest different molecular pathways of gastric carcinogenesis, consistent with the African enigma hypothesis. Further studies are needed to explore the link between *H. pylori*and other environmental factors, as well as host factors, such as polymorphisms influencing gastric cancer susceptibility, in relation to the patterns of genomic instability in gastric cancers from these different geographic areas.
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